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Abstract.  
Acute lung injury and compromised alveolar development characterize bronchopulmonary dysplasia 
(BPD) of the premature neonate. High levels of keratinocyte growth factor (KGF), a cell-cell mediator 
with pleiotrophic lung effects, are associated with low BPD risk. KGF decreases mortality in 
hyperoxia-exposed newborn rodents, a classical model of injury-induced impaired alveolarization, 
although the pulmonary mechanisms of this protection are poorly defined. These were explored 
through in vitro and in vivo approaches in the rat. Hyperoxia decreased by 30% the rate of wound 
closure of a monolayer of fetal alveolar epithelial cells, due to cell death, which was overcome by 
recombinant human KGF 100 ng/ml. In rat pups exposed to >95% O
2
 from birth, increased viability 
induced by intraperitoneal injection of KGF (2µg/g bw) every other day was associated with 
prevention of neutrophil influx in bronchoalveolar lavage (BAL), prevention of decreases in whole-
lung DNA content and cell-proliferation rate, partial prevention of apoptosis increase, and markedly 
increased proportion of SP-B-immunoreactive cells in lung parenchyma. Increased lung anti-oxidant 
capacity is likely to be due in part to enhanced CEBPα expression. By contrast, KGF neither corrected 
changes induced by hyperoxia in parameters of lung morphometry that clearly indicated impaired 
alveolarization, nor had any significant effect on tissue or BAL surfactant phospholipids. These 
findings evidence KGF alveolar epithelial cell protection, enhancing effects on alveolar repair 
capacity, and anti-inflammatory effects in the injured neonatal lung that may account, at least in part, 
for its ability to reduce mortality. They argue in favor of a therapeutic potential of KGF in the injured 
neonatal lung.  
Key words: developing lung, alveolar epithelial cell, bronchopulmonary dysplasia, lung inflammation, 
lung protection  
 3
Despite considerable obstetric and neonatal advances in the care of very low birth weight 
(VLBW) neonates, bronchopulmonary dysplasia (BPD) continues to occur among 20 to 40% of 
survivors, and new ways for combating this disease must be found. Initially described as a fibrotic 
pulmonary endpoint following severe respiratory distress syndrome, BPD has considerably evolved 
with changes in the care of VLBW infants and because of survival of lower gestational age infants 
than in the original description. It is now usually considered to result from interrupted alveolar 
development exacerbated by life-sustaining but detrimental effects of invasive neonatal practice (4, 
15). Newborn animals exposed to hyperoxia, mechanical ventilation, or airway lipopolysaccharide, 
represent models reproducing the impaired alveolarization observed in premature infants with BPD (1, 
41, 52).  
Keratinocyte growth factor (KGF), also known as fibroblast growth factor (FGF) 7, is a critical 
growth factor in lung development (10, 47) and was demonstrated as a protective agent after oxidant-
induced lung injury, both in adults and neonates (3, 6, 22, 38). This has potential clinical implication 
for BPD, since oxidative stress is a component in lung injuries leading to the occurrence of this disease 
in premature neonates (15). Moreover, previous investigation from our laboratory showed that in 
premature human neonates, high concentrations of KGF in airways were associated to low risk for 
BPD (17), whereas mechanical ventilation, another precipitating factor of BPD (15), was reported to 
down-regulate KGF expression in premature rabbits (19). Last, it was shown that KGF protected 
premature newborn rats from hyperoxic lethality, but not from hyperoxic inhibition of postnatal 
alveolar formation and early pulmonary fibrosis (22). The exact mechanisms of its protective effect 
have not yet been elucidated, however. Although a number of data about pulmonary effects of KGF 
have been gained from adult studies, they cannot be directly extended to the growing lung, since 
injuries interfere with developmental events, especially formation of definitive alveoli. Specific effects 
could therefore be expected from studies in developing animals.  
Known effects of KGF on alveolar type II epithelial cells may account for the beneficial effects 
of this growth factor in hyperoxic exposure. Actually, inducible expression of KGF in mice exposed to 
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hyperoxia protected the lung epithelium but not the endothelium from cell death, which is in keeping 
with the selective expression of KGF receptors on epithelial and not on endothelial cells (43). The 
well-established stimulatory effect of KGF on type II cell proliferation (14, 39, 53) may be 
insufficient, however, to explain its ability to restore lung tissue integrity in injured lungs (42). Indeed, 
KGF inhibited the alveolar damage induced by oxygen breathing in mice, despite the fact that its 
proliferative effect observed in normoxia was abolished under hyperoxia (6). KGF protective effect 
may be mediated by the enhancement of surfactant synthesis evidenced in adult (48, 50, 61) as well as 
fetal (14) alveolar type II cells. Thus far, however, consequences of KGF treatment for surfactant 
synthesis in the injured neonatal lung remain unknown. In the adult rat lung in vivo, the KGF-induced 
increase in surfactant protein mRNA per lung was shown to result from type II cell hyperplasia, 
whereas the mRNA content per cell was slightly diminished (63). Moreover, surfactant homeostasis 
was unchanged in type II cell hyperplasia (20). Finally, the contribution of an anti-apoptotic effect of 
KGF to its protective effect is another likely hypothesis (12, 32). Reactive oxygen species (ROS) are 
released into the alveolar space and contribute to alveolar epithelial damage in patients with acute lung 
injury. It was shown that H2O2 inhibits alveolar epithelial wound repair in large part by induction of 
apoptosis, and that apoptosis inhibition can maintain wound repair and cell viability in the face of ROS 
(24). Consistent with this assumption, KGF inhibited H2O2-induced cleavage of both pro–caspase-3 
and the substrate of caspase-3, the PARP protein, in murine lung cells (42).  
To further explore the mechanisms through which the protective effect of KGF is achieved in 
neonates, we used both in vitro and in vivo approaches of the protection of fetal/neonatal rat alveolar 
epithelial cells against disorders induced by hyperoxia.  
 
METHODS  
ANIMALS. Pregnant Sprague-Dawley rats were purchased from Charles River Laboratories 
(Saint Germain sur l'Arbresle, France). Animal studies were conducted according to criteria 
established by INSERM Animal Ethical Committee, and were performed with authorization of the 
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French Ministry of Agriculture.  
IN VITRO EXPERIMENTS  
Cell isolation and culture. Alveolar epithelial cells were obtained from enzymatically-dispersed 
fetal-rat lung cells as previously described (14). Briefly, lungs from 20-day-old fetuses were dissected 
out under aseptical conditions. Cells were dissociated by incubations in trypsin-collagenase-DNAse in 
MEM, and then seeded on plastic to allow fibroblasts to adhere for 3 successive 45min-steps. Finally, 
6 differential centrifugations were performed at 120xg for 3 min to eliminate remnant fibroblasts. 
Preliminary studies using modified Papanicolaou stain (lamellar body labeling) showed that alveolar 
type II cell purity of the final cell suspension was >90%; cell viability (trypan blue exclusion) was 
>95%. Isolated alveolar epithelial cells were counted, re-suspended in 10% FBS-MEM supplemented 
with penicillin-streptomycin, plated at 4.5 x 10
5
 
cells/well in 24-well polystyrene plates (1.9 cm 
diameter), and allowed to adhere overnight under 95% air - 5 % CO
2
. The medium was then replaced 
for fresh medium (MEM D-Val containing 0.1% fatty acid-free BSA, thereafter designated simply 
MEM). Confluent monolayers were formed by 48 h. Plates were placed either under hyperoxic 
condition (95% O
2
 - 5% CO
2
) or control condition (95% air - 5 % CO
2
) at the time of confluent cell 
wounding. The following in vitro experiments were repeated 10 times on separate cell isolates, each 
determination being done in triplicate for each isolate.  
Wound Healing Assay. To evaluate the effects of hyperoxia and KGF on the ability of cells to 
respond to a wound challenge, a linear wound was made with a pipette tip in confluent cell monolayers 
(30), and cells were washed to remove cell debris. Serum-free MEM containing or not the stimulating 
molecule (KGF) was added, and cells were placed either under control atmosphere or hyperoxia. 
Recombinant human KGF (rh-KGF, gift from Amgen, Thousand Oaks, CA, thereafter designated 
simply KGF) was added at final concentrations 10 and 100 ng/ml. Speed of wound closure by cell 
migration was evaluated through image analysis system by measurement of the area of the denuded 
surface immediately after wounding and after 24 h with aid of an inverted microscope (Zeiss, 
Thornwood, NY, USA) and a with digital camera (CDD Iris, Sony France, Paris, France). The 
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Captured images were subsequently analyzed with image analysis software (National Institutes of 
Health Image 1.55). The rate of wound repair was expressed as square millimeters per 24 hours.   
Cell mortality evaluation. At the end of the procedure, the medium was replaced by trypan-blue 
dye solution, which incorporates in dead cells. Supernatants were frozen and used for lactate 
dehydrogenase (LDH) quantification. The assay is based on measurement of LDH released into the 
medium when the integrity of the cell membrane is lost. Collected media were centrifuged at 120xg for 
7 min and frozen at –80°C until determinations. Defrozen media were incubated under protection from 
light for 30 minutes with the substrate mixture in 96-well plates using LDH assay kit based on the 
reduction of tetrazolium salt INT into formazan (Roche Diagnostics, Meylan, France). Optical density 
of formazan was read at 490 nm on a plate reader (Molecular Devices, Saint Grégoire, France).  
Cell viability. Cell viability was evaluated using the tetrazolium salt (Sigma-Aldrich, Saint-
Quentin Fallavier, France) MTT colorimetric assay (34). Briefly, on day 2 of hyperoxia exposure, 
62 µl of a 0.2% MTT solution were added to each well containing 0.5 ml of MEM, and the mix was 
incubated for 2.5 h at 37°C to perform MTT metabolization. The medium was then replaced by 0.5 ml 
of pure DMSO for 10 min. Then, 200 µl of supernatant were recovered and transferred to a 96-well 
plate to measure absorbance at 520 nm.  
Evaluation of in vitro cell proliferation by 5-Bromo-2'-Deoxyuridine (Brd-U) labeling. 
Proliferation was evaluated using the Cell proliferation ELISA Brd-U kit (Roche Diagnostics, Meylan, 
France). Briefly, cells were seeded in 96-well plates (200µl per well of a cell suspension adjusted to 
450,000 cells/ml), and cultured as usual. On day 2 of culture, cells were labeled with Brd-U for 24 h 
while exposed to hyperoxia or air, in the presence or absence of rh-KGF. The DNA was then 
denaturated by adding Fix Denat solution for 30 min at 20°  C, then exposed to peroxydase-conjugated 
anti-BrdU antibody for 90 min. The reaction was stopped and the optical density was determined at 
492nm.  
IN VIVO EXPERIMENTS  
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Animal treatments. Rat pups born in the laboratory were divided into groups of equal numbers 
and body weights between each experimental group (i.e., room air or O2 exposure), and kept on a 
12:12-h light-dark cycle. Food pellets and water were given ad libitum to the dams.  
Litters of randomly divided rat pups and their dams were placed in Plexiglas exposure chambers 
(Charles River Laboratories) and run in parallel with either >95% or 21% (room air) fraction of 
inspired oxygen, as previously reported (26) from day 0 to day 10. O2 concentrations were monitored 
regularly. Because adult rats have limited resistance to high O2, the dams were exchanged daily 
between O2-exposed and room air-exposed litters. Chambers were opened for 20 min every day to 
switch dams treat rat pups, and clean cages. Recombinant human KGF (2 µg/g body weight) or vehicle 
(controls) was injected intraperitoneally at birth and on days 1, 3, 5 and 7. Lung availability of rhKGF 
after intraperitoneal injection of 2 µg/g was evaluated preliminary by a specific human kit ELISA 
(R&D Systems, Lille, France). Lung concentration was 20 pg/mg lung tissue 6 hours after injection, 
and decreased to 4 pg/mg after 24 hours.  
On days 5, 7 or 10, rat pups were killed by an intraperitoneal overdose of sodium pentobarbital 
(70 µg/g bw) and were exsanguinated by aortic transsection. Lungs were either immediately lavaged, 
or fixed for morphometric/morphologic analysis, or dropped in liquid nitrogen and kept frozen at –
80°C until further assays.  
BAL and cell count in lung fluid. On day 7, rat pups were placed in supine position, and a 
cannula was inserted in trachea. Isotonic saline was gently instilled with a syringe, then withdrawn. 
BAL was performed 12 times with 0.33ml sterile saline, and the 12 lavage samples were pooled. Total 
cell counts were performed on an aliquot fraction with a hemocytometer, then samples were 
centrifuged at 300xg for 7 min. Cell pellets were resuspended in adequate volume to obtain 10
6
 
cells/ml, and differential cell counts were performed on cytospin preparations stained with Diff-Quik 
(Dade Behring, Paris-La Défense, France). A blinded observer counted a minimum of 300 cells to 
establish the differential cell count. Lavaged lung tissues were discarded.  
Lung morphometry analyses. Ten-day-old pups were used. Methods used herein have been 
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described in details previously (58). Briefly, lung fixation was performed by tracheal infusion of 
neutral buffered paraformaldehyde (PFA) at 20cm H2O pressure, and fixed lung volume was measured 
by fluid displacement. After routine processing and paraffin embedding, 4µm-thick mediofrontal 
sections through both lungs were stained with hematoxylin-phloxin-saffron (HPS). All morphometric 
evaluations were made by one single observer (X.D.) who was unaware of group assignment. Volume 
densities of alveolar airspace, airways, blood vessels larger than 20µm in diameter, and interstitial 
tissues, and the alveolar surface density were determined using the point counting and mean linear 
intercept methods (59) at an overall magnification of ×440 using a 42-point, 21-line eyepiece graticle 
on 20 fields per animal (10 per lung) with a systematic sampling method from a random starting point. 
To correct for shrinkage associated with processing, area values were multiplied by 1.22 as previously 
calculated. All morphometric data were expressed as relative, absolute, and specific values, as 
described (13).  
Surfactant phospholipid determination. Lipids were extracted from lung tissue homogenates (5d-
old pups) or from BAL fluid (7d-old pups) by chloroform : methanol : water 1:2:0,8 (vol/vol/vol). 
Individual phospholipids were separated by thin layer chromatography, and disaturated 
phosphatidylcholine (DSPC) was separated by osmium tetroxide and thin layer chromatography, then 
total phosphatidylcholine (PC), phosphatidylglycerol (PG) and DSPC spots revealed by iodine fixation 
were scrapped, mineralized, and phosphate was assayed as described previously (8).  
Lung DNA content. Lung DNA was determined on the pellet of phospholipid extraction from 
lung tissue (5d-old pups) by the diphenylamine colorimetric method as described previously (8).  
Determination of lung cell proliferation by 5-Bromo-2'-Deoxyuridine labeling (Brd-U). The cell 
proliferation kit from GE Healthcare (Buckinghamshire, UK) was used. Seven dayold rats were 
injected intraperitoneally with Brd-U 2 hours before sacrifice. Extracted lungs were fixed through a 
polyethylene tracheal cannula with OCT embedding medium for frozen tissue specimens (Tissue-Tek, 
Sakura Finetek Europe B.V., Zoeterwoude, The Netherlands) mixed with PBS, then frozen in liquid 
nitrogen and stored at –80°C. Five–micrometer-thick tissue slices were cut with a cryostat (Jung 
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CM3000; Leica Microsystems GmbH, Wetzlar, Germany). Tissue sections were analyzed by 
immunohistochemistry according to the manufacturer’s recommendations: incorporated Brd-U was 
localized using a specific monoclonal antibody and peroxidase-conjugated antibody to mouse 
immunoglobulin, polymerising diaminobenzidine (DAB) in the presence of cobalt and nickel (blue-
black staining at sites of Brd-U incorporation). Preparations were counterstained with nuclear red. The 
area of Brd-U positive nuclei was quantified and compared with the total area of nuclei in the same 
region, labeled by nuclear red using Perfect Image sofware (Clara Vision, Massy, France). A random 
examination of 10 fields for each right and left lung was performed. Three neonates were included in 
each condition. Results were expressed as percentage of lung area occupied by Brd-U-positive cells.  
Determination of surfactant protein B (SP-B) immunoreactive cells. Immunostaining of 
postnatal day-10 lung tissue was performed using 5µm paraffin sections that were deparaffinized and 
rehydrated. Endogenous peroxydase activity was quenched for 30mn with 3% H2O2 in phosphate-
buffered saline (PBS). Nonspecific antigenic sites were blocked by incubation with 2% normal goat 
serum for 1 hour. Labeling was obtained by incubation with anti-SP-B rabbit polyclonal antibody (gift 
from J.A.Whitsett, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA) diluted 
1:500, PBS washing, then incubation with horseradish peroxydase-conjugated goat anti-rabbit 
antibody (Santa Cruz Biotechnology, le Perray, France). Sections were covered with diaminobenzidine 
tetrahydroxychloride (Vector Laboratories), counterstained with methyl green, dehydrated, and 
observed with light microscope. As negative control, nonimmune rabbit serum was used. Five samples 
of 4 fields were counted for each tissue section. Three neonates were included for each condition. 
Mean total number of cells per field and percentage of SP-B-positive cells are presented.  
Determination of the proportion of apoptotic lung cells. The terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL) assay was used to monitor the extent of DNA 
fragmentation as a measure of apoptosis in paraffin-embedded sections of lungs from 10d-old pups. 
The assay was performed with ApopTag Peroxidase in situ Detection Kit according to the recommendations of the manufacturer 
(Qbiogen, Illkirch, France). Sections were counterstained with methyl green, dehydrated and observed in light 
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microscopy. Quantification of TUNEL-positive cells was performed similar to that of BrdU labeling.   
Western-blot analysis of caspase 3. Lung tissues collected on days 5 and 10 were homogenized 
in RIPA buffer containing protease inhibitors cocktail (Roche Molecular Biochemicals, Meylan, 
France). Homogenates were centrifuged 10 min at 10,000xg, and protein concentration was 
determined in supernatants (Bradford assay method). Western blot analysis was performed to evaluate 
the activated-caspase 3 level in lung homogenates at 5 and 10 days. One hundred µg of proteins were 
electrophoresed on a 12% SDS-polyacrylamide gel, and transferred then onto polyvinylidene fluoride 
membrane (Millipore, Saint-Quentin-en-Yvelines, France); transfer was checked by stain with 
Ponceau S dye (Sigma, L’Isle-d’Abeau, France) that also served as loading control. Membranes were 
exposed overnight at 4°C to a rabbit anti-caspase 3 antibody (Cell Signaling Technology, Danvers, 
MA, USA) diluted 1:1000, incubated for 1h with horseradish peroxidase-conjugated goat anti-rabbit 
IgG antibody (Santa Cruz Biotechnology, Santa Cruz, USA) diluted 1:5000, then in Enhanced 
Chemiluminescence detection reagent (Amersham Bioscience) for 1 min, and finally exposed to 
Kodak BioMax MS film for 2 min. Densitometry analysis of blots was performed using the VersaDoc 
Imaging system (BioRad) with the Quantity One program.  
RNA extraction and quantitative RT-PCR (qPCR) analysis. Total RNA was extracted using the 
guanidinium isothiocynate method (TRIzol reagent, Invitrogen, Cergy-Pontoise, France), followed by 
purification with Rneasy columns (Qiagen, Courtaboeuf, France). RNAs were reverse-transcribed 
using 2µg of total RNA, Superscript II reverse transcriptase, and random hexamer primers (Invitrogen) 
according to the supplier’s protocol. Real-time PCR was performed on ABI Prism 7000 device 
(Applied Biosystems, Courtaboeuf, France) using initial denaturation for10 min at 95°C, and two-step 
amplification program (15 s at 95°C followed by 1 min at 60°C) repeated 40 times. Melt curve 
analysis was used to check amplification of a single specific product. Reaction mixtures consisted of 
25ng cDNA, SYBR Green 2X PCR Master Mix (Applied Biosystems), and forward and reverse 
primers for the examined transcripts (Table 1) in a reaction volume of 25µl. Primers were designed 
using Primer Express software (Applied Biosystems). Real-time quantification was monitored by 
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measuring the increase in fluorescence caused by binding of SYBR Green dye to double-stranded 
DNA at the end of each amplification cycle. Relative expression was determined using the ∆∆Ct 
(threshold cycle) method of normalized samples (∆Ct) according to the manufacturer’s protocol in 
relation to the expression of a calibrator sample and of 18S rRNA used as a reference. Each PCR run 
included a no-template control and a sample without reverse transcriptase. All measurements were 
performed in triplicates.  
STATISTICAL ANALYSIS. Data are expressed as means ± s.e.m. Differences between three or 
more groups were evaluated using an ANOVA or Kruskal–Wallis test, as appropriate. Differences 
between two groups were evaluated using Student’s t test, Fisher's post hoc test, or Mann–Whitney 
test, as appropriate and stated in legends. Overall rat-pup survival in relation to treatment was 
evaluated by Kaplan–Meier survival function, and the log-rank test was used for comparisons between 
treatment groups. All calculations were performed with Statview software version 5.0 (SAS Institute 
Inc, Cary, NC). A p value < 0.05 was considered to be statistically significant.  
RESULTS  
IN VITRO EXPERIMENTS  
Effects of hyperoxia on wound healing of alveolar type II cell monolayers. Hyperoxia markedly 
impaired wound healing, decreasing the rate of wound closure by approximately 30% (Fig. 1A). This 
impairment was mainly due to cell death, presumably mainly because of necrosis, as observed by 
numbering of trypan-blue labeled cells that were increased about 8-fold (Fig. 1B). Cell death was 
confirmed by an increase of LDH release in conditioned medium (Fig. 1C). Cell viability assessed by 
MTT test was decreased by 40% under hyperoxia (Fig. 1D) whereas cell proliferation rate was not 
different (Fig. 1E).  
Effects of KGF on alveolar type II cells exposed to hyperoxia. Under control condition (95% air 
- 5% CO2), KGF alone changed neither the speed of wound healing, nor cell death as evaluated either 
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by trypan-blue exclusion or LDH determination, nor cell viability and proliferation (data not shown). 
Under 95% O2, KGF at the concentration 10 ng/ml had no effect on all the studied parameters, but 
when elevated to 100 ng/ml, KGF increased the closure speed of the wound about twice (p<0.01, Fig. 
2A), and it markedly reduced the dead-cell surface area (p<0.001, Fig. 2B) and slightly decreased the 
level of LDH released in culture medium (p=0.03 Fig. 2C). KGF 100ng/ml also increased about 75% 
cell viability as evaluated by MTT assay (p=0.03, Fig. 2D), but did not change the rate of cell 
proliferation (Fig. 2E). Interestingly, addition of 5% FBS to control medium, which increased wound 
closure rate about 3 times, failed by contrast with KGF to diminish cell-death area extension and LDH 
release (not shown).  
IN VIVO EXPERIMENTS  
Mortality rate. KGF significantly improved the survival of neonates (Fig. 3). On day 10, 14 out 
of 19 neonates exposed to hyperoxia that had received intraperitoneal KGF were still alive (73,7%), 
whereas only 6 of 18 neonates exposed to hyperoxia that received the vehicle solution only were alive 
(33,3%, Log Rank: p=0.004).  
Lung morphometry. On day 10, survivors were evaluated for lung morphometry (Table 2). Lung 
volumes did not differ between subgroups. Hyperoxia significantly altered lung growth. Decreased 
alveolarization was evidenced by reduced alveolar surface density (Sv(a,p); p < 0.001), reduced total 
alveolar surface (Sa; p < 0.001), reduced interstitial volume density (Vvi; p < 0.001), and increased 
alveolar airspace volume density (Vva; p < 0.001). Vascular volume density (Vvv) was also 
significantly reduced by hyperoxia (p = 0.03). No change was observed in airspace volume density of 
airways (VvA). KGF did not attenuate hyperoxia-induced lung development alterations, and decreased 
Sv(a,p).  
Cells in BAL. Cell number and differential count in BAL were determined on day 7, when 
hyperoxia-induced mortality rate began being significantly different between KGF-treated rat pups and 
controls. Recovery of instilled saline was similar in all groups. No significant increase in total BAL 
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cell count was observed in newborn rats exposed to hyperoxia (Fig. 4). However, the distribution of 
cells was significantly changed, with a decrease in alveolar macrophage proportion (p = 0.01), and a 
significant neutrophil influx into alveoli (p < 0.005); the latter were extremely rare in basal condition. 
KGF prevented neutrophil influx (p < 0.004).   
Lung DNA content and proportion of SP-B immunoreactive cells. Hyperoxia induced a 40% 
decrease in whole-lung DNA content on day 5, which was totally prevented by KGF injections (Fig. 
5). To focus on this KGF-induced cell protection in distal lung, we evaluated on lung sections both the 
total number of nuclei in alveolar walls and the proportion of SP-B-expressing alveolar cells, 
considered as representing alveolar type II cells. Hyperoxia decreased by about 40% the total number 
of cells in alveolar walls in newborns having received the vehicle only (p < 0.001, Table 3). This 
decrease was not observed for SP-B-positive cells, which means that the proportion of SP-B-positive 
cells was significantly enhanced under hyperoxia. KGF had a significant effect on SP-B-positive cells 
(Table 2), with both an increase in their absolute number in room air (p = 0.04 as compared to vehicle-
injected controls) and an increase in their percentage under hyperoxia (p < 0.001 as compared to 
vehicle-injected controls exposed to O2).  
Lung parenchymal cell proliferation. Brd-U incorporation into lung cells was evaluated at day 7. 
The percentage of cells exhibiting Brd-U incorporation was significantly reduced by hyperoxia (p < 
0.002), but was not significantly changed by KGF (Fig. 6). Mean values were 9.6 ± 1.1, 6.4 ± 1.9, 2.7 
± 1.2, and 2.0 ± 0.5 % of total cells in air-control, air-KGF, hyperoxia-control, and hyperoxia-KGF rat 
pups, respectively.  
Apoptosis. Level of apoptosis evaluated by TUNEL assay was about 1% of cells in newborns 
exposed to room air (Table 3). Hyperoxia induced a 2.3-fold increase in this proportion (p < 0.05). 
KGF treatment tended to prevent this increase since the value, intermediate between that of controls in 
air and hyperoxia, was no longer different to that of the former although not significantly different 
from that of the latter. Caspase 3 was evaluated by semi-quantitative western-blot analysis (Fig. 7). 
Hyperoxia markedly decreased lung caspase 3 content, which was significantly more pronounced on 
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day 10 (p < 0.005 between stages). KGF induced a significant decrease in caspase 3 content on day 5, 
independently of air or oxygen breathing (p < 0.001), but not on day 10. The fraction of caspase 3 that 
was activated significantly increased from day 5 to day 10 in room air neonates (p < 0.03). Hyperoxia 
significantly decreased activated caspase 3 (p < 0.02). No significant difference was associated to KGF 
treatment.  
Surfactant phospholipids. DSPC and PG, the major phospholipids components of surfactant, 
were determined in whole lung tissue on day 5 (Table 4). Hyperoxia did not significantly change 
DSPC concentration, whereas it significantly decreased PG concentration by about 25%. KGF 
treatment had no significant effect on these changes. DSPC was also determined in BAL on day 7 and 
was found to be increased by hyperoxia; KGF induced changes in the proportion of DSPC neither in 
room air nor under hyperoxia (Table 4).  
Gene expression of EGFR, TGFα, C/EBPα and Vnn1. To further explore the possible underlying 
molecular mechanisms of KGF effects, qPCR was used to quantify the steady state levels of the 
transcripts of (i) transforming growth factor (TGF) α and its receptor epidermal growth factor receptor 
(EGFR) previously shown to be involved in the mediation of KGF-enhanced spreading and migration 
of adult alveolar type II cells (2), and (ii) of the transcription factor CAAT enhancer binding protein α 
(C/EBPα) and the ectoenzyme with pantetheinase activity Vanin 1 (Vnn1) known to be involved in 
pulmonary cytoprotection during hyperoxia exposure in mice (40, 62). These were determined in 5d-
old rat pups. Hyperoxia increased the transcripts of EGFR and TGFα about 2.3 and 1.8 times, 
respectively, either in the absence or presence of KGF (Fig. 8). The latter did not change significantly 
these expression levels, although mean values were slightly higher. C/EBPα transcript was not 
significantly changed by hyperoxia; KGF did not enhance its expression in the lung of pups exposed to 
room air, but the transcript was by contrast enhanced 88% (p<0.05) in animals simultaneously exposed 
to O2 and KGF (Fig. 8). The steady state level of Vnn1 transcript was increased in both O2–vehicle and 
O2–KGF groups as compared to groups in room air, but the increase was statistically significant only 
for the O2–KGF group due to the wide dispersion of individual data in the O2–vehicle group (Fig. 8).  
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DISCUSSION  
The present study was undertaken to explore at the cellular level possible mechanisms of KGF 
action susceptible to account for its protective effects towards the exposure of the developing lung to 
hyperoxia, used as a model of alveolar injury. We report enhanced rate of alveolar cell wound closure 
in vitro, and maintenance of lung cell content in vivo, likely to be due to enhanced survival of alveolar 
epithelial type II cells.  
Most of studies demonstrating a protective effect of KGF against lung injury used the 
intratracheal route (38, 54) rather than systemic route (6), whereas we administered KGF 
intraperitoneally and during oxygen exposure. Possible mechanisms to explain the protective effects of 
KGF in acute lung injury have been recently reviewed (57) and are mainly based on effects on alveolar 
and airway epithelial cells, including increased proliferation (33, 39, 53, 63), increased surfactant 
production (14, 27, 50, 61), enhanced DNA repair (12, 51, 60), and decreased apoptosis (12, 43). 
These effects were however mainly studied in adult animals or cells, and scarcely examined in the 
neonatal period.  
In this study, we demonstrate the protective effect of exogenous KGF on alveolar epithelial cells 
in neonatal rats exposed to hyperoxia, but we could not rely this effect to known effects of KGF 
observed in adult animals, except for the increase of C/EBPα expression. Giving KGF to newborn rats 
was not significantly associated to increased lung cell proliferation rate, decreased lung cell apoptosis, 
or increased production of surfactant, but was however shown to have a significant protective effect on 
alveolar type II cells and to significantly reduce alveolar neutrophil influx. Nevertheless, KGF 
treatment, although improving type II cell survival, did not prevent disrupted alveolarization, which is 
in keeping with previous report (22).  
Indeed, the present study presents limitations. Changes induced by KGF in cultured cells 
exposed to hyperxoxia suggest possible protection/repair mechanisms, but do not demonstrate that 
these mechanisms are effective in vivo, because the cultured epithelial monolayer and the in vitro 
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mechanical injury are obviously limited models of the alveolar epithelium and of in vivo injuries, 
respectively. The in vivo model using >95% O
2
 is extremely severe and might have masked possible 
effects of KGF susceptible to occur with a milder injury model. This condition was used because it is 
the one that had previously allowed KGF protection against hyperoxic lethality to be evidenced (22). 
Lastly, although we explored a number of possible KGF effects, the investigation could not be 
exhaustive, considering the pleiotrophic effects of this growth factor. For instance, although wet-to-dry 
lung weight ratio was not changed by KGF in rat neonates (22), anti-edematous effect might have 
contributed to lung protection because KGF has been reported to enhance sodium and fluid transport 
and to prevent alveolar edema in a variety of experimental models of lung injury (3, 25, 44, 56, 65). 
Anti-edematous effect could however hardly be explained by maintenance of the type II cell pool, 
since these cells account for 3-5% of alveolar surface only, or by restoration of damaged alveolar 
barrier by transdifferentiation of type II into type I cells, a process that is likely to occur principally 
during recovery after arrest of hyperoxic exposure. Direct effect of KGF on fluid transport by type I 
cells, which cover the major part of alveolar surface, appears possible since evidence has been given 
that type I cells not only reabsorb water, but also contain functional sodium channels and appear 
responsible for the bulk of transepithelial Na
+
 transport in the lung (28). Last, FGF receptors inhibition 
has evidenced the key role of the FGF system in regulating vascular integrity (35). KGF might 
therefore have also prevented fluid leakage and/or favored fluid reabsorption through protection of 
pulmonary microvascular network. It cannot be ruled out that these mechanisms, together with those 
reported herein, have contributed to enhanced survival in KGF-treated rat pups exposed to hyperoxia. 
DNA determination used to evaluate lung cell number indicated that oxygen damage was 
associated to cell loss, and that KGF treatment prevented this effect. Oxygen exposure is known to 
markedly reduce the turnover of alveolar cells. Previous study in adult mice showed no significant 
restoration by KGF (6). In the present study, KGF was able to prevent oxygen-induced mortality in 
neonatal rats despite a low lung-cell proliferation rate, arguing for a lung protective effect that is not 
necessarily associated with its capacity to sustain epithelial cell proliferation since BrdU intake 
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increased neither in vivo nor in vitro.  
In fact, the main mechanism indicated by our results is the protective effect of KGF towards 
hyperoxia-induced cell toxicity. Exposure to oxygen is known to result in death of alveolar epithelial 
and endothelial cells (7, 16). It was also suggested that KGF exerted in adult mice a protective effect 
on epithelial cells (6). Consistently, we report that KGF protected fetal alveolar epithelial cells exposed 
to hyperoxia in vitro, as evaluated by the extent of cell-death area, by the level of released LDH, and 
by increased cell viability. In vivo, prevention of lung DNA decrease and elevated percentage of SP-B-
positive cells were also consistent with protection and maintenance of alveolar type II epithelial cells. 
A reduced number of type II cells was similarly observed previously in neonatal mice recovering from 
hyperoxia (64), and the KGF-induced increase in type II cell number is consistent with previous 
findings in adult animals subjected to oleic-acid-induced lung injury (54). KGF overexpression using 
adenoviral vector was recently shown to induce proliferation of surfactant protein C-positive cuboidal 
cells, i.e. alveolar type II cells, and also to prevent lung injury (3), which in keeping with present 
findings. Type II cell preservation is crucial for repair process since alveolar type I cells, which are the 
most sensitive to injury, reconstitute from type II cells. Higher recovery potential may result from 
higher percentage of surviving type II cells post injury, which confers therapeutic value to KGF.  
A recent investigation showed that the transcription factor C/EBPα is required for cytoprotection 
of type II cells during hyperoxia, and that this effect is likely to be mediated through the transcriptional 
regulation of the vanin-1 gene (Vnn-1) to trigger a variety of cellular redox-sensitive signaling 
processes (62). Vanin-1 is a membrane-bound protein with pantetheinase activity that produces 
cysteamine, a potent anti-oxydant, and indeed, tissues of Vnn1-deficient mice lack cysteamine (40). 
We therefore hypothesized that cytoprotection of alveolar cells by KGF could be mediated by 
enhanced C/EBPα and/or Vnn1 expression. The transcript level of C/EBPα was effectively increased 
in the lung of rat pups exposed to hyperoxia and treated by KGF as compared with both air-exposed 
controls and hyperoxia-exposed pups injected with the KGF vehicle. Consistent with the present 
finding, we had previously evidenced enhanced C/EBPβ expression by KGF in isolated type II cells 
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(5), but C/EBPα expression was rapidly lost in vitro, which prevented from determining KGF effects. 
KGF-increased expression of C/EBPα, which had not been reported formerly, provides a mechanistic 
support to type II cytoprotection against hyperoxia, likely to have contributed at least for a part to the 
decreased mortality of rat pups. By contrast, the Vnn1 transcript was augmented as a consequence of 
the sole exposure to hyperoxia, and was not further enhanced by KGF. The effects of enhanced 
C/EBPα could therefore be mediated by the expression control of other genes the product of which are 
involved in anti-oxidant defense mechanisms. Moreover, the status of Vnn1 appears to be rather 
complex since Vnn1-deficient mice have been paradoxically reported to exhibit resistance to oxidative 
injury in spite of the absence of cysteamine, due to elevated stores of glutathione (9).  
Despite increased type II cell survival, and although KGF has been reported to enhance the 
synthesis of surfactant components in vitro (14, 50, 61) and in vivo (27), we found no effect of KGF 
on lung surfactant content in hyperoxia-exposed rat neonates. Indeed, the effects of hyperoxia on 
surfactant synthesis seem to be complex and may have interfered with those of KGF. Thus, the 
expression of surfactant protein genes is known to be up-regulated by injury including hyperoxia or 
lipopolysacharide exposure, in adult animals (37, 49) as well as in newborns (18). Phospholipid 
compartment had not been investigated in depth formerly in this condition. Alterations in individual 
phospholipid components may differ from those of surfactant proteins since we found a decrease in 
lung tissue PG, but an increase in BAL DSPC. On the other hand, surfactant homeostasis was 
maintained in rats in vivo following tracheal instillation of KGF despite type II cell hyperplasia (20). 
Although we did not evaluate the pulmonary content in surfactant proteins in the present study, it 
seems unlikely that beneficial effects of KGF on survival may relate to surfactant.  
We also evaluated in vitro the effect of KGF on wound repair. By contrast with adult type II 
cells (23), KGF did not enhance wound closure in fetal cells under normoxic condition. Nonetheless, it 
restored wound closure ability under hyperoxia, which appeared to be due mainly to prevention of cell 
death. This suggests increased repair potential of type II cells in the presence of KGF. On a 
mechanistic point of view, previous investigation (2) had evidenced that intratracheal KGF in vivo 
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enhanced the repair potential of rat type II cells by nonmitogenic mechanisms through increased 
spreading and migration, as assessed in vitro on isolated cells. This was shown to require the mediation 
of TGFα through binding to EGFR (2). We therefore hypothesized that the effects of KGF reported 
herein could be mediated, at least for a part, by a control of either TGFα or EGFR expression. In fact, 
the transcripts of both these proteins were markedly elevated by hyperoxic exposure in vivo, consistent 
in the instance of TGFα with previous observation in neonatal rabbits (55). KGF, however, induced 
significant change neither under normoxia nor under hyperoxia. The mechanism evidenced in adult rat 
cells therefore does not seem to account for the protective effects of KGF in rat neonates.  
Cell death resulting from oxygen-induced adult lung injury presents features of both necrosis 
and apoptosis (7). Our data suggest that nonapoptotic cell death is the predominant effect of hyperoxia 
in newborns rat lungs as indicated by lack of increase in activated caspase-3 and by the slight increase 
in TUNEL-positive cell number. This is also clearly supported by trypan-blue exclusion study in 
cultured cells, although we did not evaluate apoptosis directly in this instance. Nonapoptotic cell death 
was previously recorded in cultured human lung epithelium exposed to O
2
, with swelling of nuclei, 
increase in cell size, and no evidence for any augmentation in the levels of caspase-3 activity (21). The 
dissociation we observed between TUNEL and caspase 3 findings is in agreement with the 
involvement of multiple apoptotic pathways in hyperoxia (7). Thus, in adult mice, despite the evidence 
of changes specific for apoptosis, including internucleosomal DNA degradation, the marked increase 
in lung RNA or protein levels of p53, bax, bcl-x, and Fas, which are known to be expressed in certain 
types of apoptosis, contrasted with the absence of increase in proteases of the apoptosis "executioner" 
machinery, such as caspase 1 or 3 (7). Furthermore, it has not been possible so far to attenuate oxygen-
induced injury by anti-apoptotic strategies (7). In fact, the main inducer of activated caspase 3 in the 
present study was postnatal age. Apoptosis is known to be involved in lung remodeling during normal 
pre- and postnatal development in man and rat (45, 46). Postnatally, the role of apoptosis appears to be 
to rid the lung from excess fibroblasts and epithelial cells so as to increase the gas exchange surface 
area (31, 46). Thus, apoptosis levels were shown to abruptly increase at the time of spontaneous birth, 
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up to 9% of cells, and to rapidly decrease then to around 1% of cells by day 2 of life (31). It remained 
low during alveolar septation, a stage that is conversely characterized by a high index of proliferation, 
but from day 13 (i.e. after completed septation), the number of lung fibroblasts undergoing apoptosis 
increased 4 to 5-fold (11).  
Last, we found that KGF prevented alveolar neutrophil influx in hyperoxia-exposed newborns. A 
similar effect of KGF was previously shown in adult mice subjected to intratracheal acid instillation, a 
decrease in MIP-2α gradients between BAL fluid and plasma being suggested as the underlying 
mechanism (36). Presumably, cytoprotection of alveolar epithelial cells diminished inflammation 
signals involved in neutrophil recruitment, including expression of a variety of cytokines. Decreased 
neutrophil influx might have in turn diminished secondary injury to the epithelium. Moreover, KGF 
was also shown to decrease ICAM-1 and VCAM-1 expression and neutrophil adherence in bronchial 
epithelial cells, suggesting its involvement in the resolution of the inflammatory reaction (29).  
 
In conclusion we report evidence for KGF protection of alveolar epithelial cell probably through 
enhanced anti-oxidant defense mechanisms, enhancing effects on alveolar repair capacity, and anti-
inflammatory effects in the injured neonatal lung that may account, at least for a part, for the ability of 
the factor to reduce pup mortality. Although no effects on impaired alveolarization were observed, this 
argues in favor of a therapeutic potential of KGF in neonatal chronic lung disease.  
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FIGURE LEGENDS  
 
Fig. 1. Effects of hyperoxia on cultured alveolar epithelial cells: (A) wound closure rate, (B) cell-death 
area extension around the wound after 24h assessed by trypan blue staining, (C) cell mortality 
estimated by LDH release in medium, (D) cell viability assessed by MTT test, (E) cell proliferation 
evaluated by Brd-U incorporation (O.D.: optical density). Cells were cultured in serum-free D-VAL 
MEM. Control condition was 95% air - 5% CO2. Hyperoxia (95% O2 - 5% CO2) decreased the rate of 
wound closure, increased cell mortality, decreased cell viability, but did not affect cell proliferation. 
Values are mean ± s.e.m. of data from 10 separate experiments. Two-group comparisons by Student’s t 
test; significant difference with cells in air-CO2 for: ***p<0.001.  
 
Fig. 2. Effects of KGF on cultured alveolar epithelial cells maintained under hyperoxia (95% O2 - 5% 
CO2): (A) wound closure rate, (B) cell-death area extension assessed by trypan blue staining (C) cell 
mortality assessed by LDH release in medium, (D) cell viability assessed by MTT test, (E) cell 
proliferation evaluated by Brd-U incorporation. Results are expressed as percent of mean control value 
(cells in serum-free D-Val MEM exposed to room air). KGF 10ng/ml had no significant effect whereas 
KGF 100ng/ml increased the rate of wound closure, decreased cell death, and increased cell viability, 
but had no effect on cell proliferation. Values are mean ± s.e.m. of data from 10 separate experiments. 
Multiple comparisons by ANOVA and two-group comparisons by Fisher's post hoc test; significant 
difference with control for: *p<0.05, ***p<0.001; with hyperoxia for: +p<0.05, +++p<0.001.  
 
Fig. 3. Survival rate in newborn rats exposed to hyperoxia from birth to day 10 of age, which received 
intraperitoneally either KGF (dashed line and squares; n = 19) or vehicle (solid line and circles; n = 
18). KGF markedly reduced the rate of mortality (p=0.004 on day 10).  
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Fig. 4. BAL cell contents in 7-day-old rats exposed to room air or hyperoxia from birth. Total cell 
(grey bars), alveolar macrophage (open bars), and neutrophil (closed bars) counts are presented. 
Values are mean ± s.e.m on 6 individuals in each group. Multiple comparisons by Kruskal-Wallis test 
and two-group comparisons by Mann-Whitney test; significant difference between groups for: **p < 
0.01.  
 
Fig. 5. Whole-lung DNA content determined in 5-day-old rats exposed to room air or hyperoxia from 
birth. For each condition, newborns received either KGF (grey bars) or vehicle (open bars). Values are 
mean ± s.e.m on 6 and 7 individuals per group in room air and hyperoxia, respectively. Multiple 
comparisons by ANOVA and two-group comparisons by Fisher's post hoc test; significant difference 
between groups for: ***p < 0.001. Hyperoxia diminished DNA content, i.e. total lung cell number, 
which was prevented by KGF treatment.  
 
Fig. 6. In vivo BrdU incorporation into alveolar lung cells (black labeling of cell nuclei, arrows): (A) 
control (room air + vehicle), (B) room air + KGF, (C) Hyperoxia + vehicle, (D) Hyperoxia + KGF. See 
text for quantitative analysis.  
 
Fig. 7. Lung caspase 3 content evaluated on days 5 and 10 by western-blot. Upper panel: 
representative blots with 35kDa band of non activated caspase 3, and 17 and 19 kDa bands of activated 
caspase 3; left, 5 days, right 10 days (lanes: vehicle injections in air, KGF injections in air, vehicle 
injections in O2, KGF injections in O2); ponceau S labeling was used as loading control. Lower panel: 
histogram represents mean values ± s.e.m. of densitometric analysis of blots (n=4 individuals per 
group). Open bars: newborns having received the vehicle; grey bars: newborns treated with KGF; 
lower hatched part of bars: activated fraction of caspase 3. Hyperoxia significantly decreased lung 
caspase-3 content. KGF induced a significant decrease in caspase 3 content on day 5, independently of 
air or oxygen breathing, but not on day 10. The activated fraction of caspase 3 significantly increased 
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from day 5 to day 10 in room air neonates. Hyperoxia significantly decreased activated caspase-3 
fraction (p< 0.02), but no significant restoration was associated to KGF treatment. Multiple 
comparisons by Kruskal-Wallis test and two-group comparisons by Mann-Whitney test; significant 
difference with room air for: ***p<0.001; significant difference with vehicle-injected pups for: § p< 
0.001.  
 
Fig. 8. Steady state level of the transcripts for epidermal growth factor receptor (EGFR), transforming 
growth factor α (TGFα), CAAT/enhancer-binding protein α (C/EBPα), and Vanin-1 in the lung of 5d-
old rat pups. Hyperoxia increased EGFR and TGFα transcripts; KGF increased the C/EBPαtranscript 
in the presence of hyperoxia. Multiple comparisons by Kruskal-Wallis test and two-group comparisons 
by Mann-Whitney test; significant difference with controls in room air for: *p<0.05; significant 
difference with vehicle-injected pups under hyperoxia for: § p< 0.05.  
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Table 1. Primer sequences for qPCR 
 
 
 
Amplicon sizes were 75, 76, 71 and 101 bp for EGFR, TGFα, C/EBPα and Vnn1, 
respectively 
 
 
Genes Primers  (5’ – 3’) Accession # 
 
EGFR Fw:  GGACTGTGTCTCCTGCCAGAA Rv:  GGTTCCCCCTCCAGGATGT   NM_031507 
TGFα Fw:  CCCTGGCTGTCCTCATTATCA Rv:  GCACGGCACCACTCACAGT   NM_012671 
C/EBPα Fw:  TGCGCAAGAGCCGAGATAA Rv:  CGGTCATTGTCACTGGTCAACT   NM_012524 
Vnn1 Fw:  GGCTATAGGCATGGGAGTCAAT Rv:  AGGCCCGTGGAGAATCG NM_001025623 
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Table 2. Lung morphometry analysis in rat pups treated by rhKGF in room air or under 
hyperoxia 
 
 Room air  Hyperoxia  
 controls rhKGF controls rhKGF 
Body weight (g) 20.6 ± 0.5 20.1 ± 0.4 21.1 ± 0.7 20.8 ± 1.0 
Lung volume (ml) 1.05 ± 0.05 1.05 ± 0.05 1.10 ± 0.08 1.00 ± 0.05 
Sv(a,p) (cm
2
/cm
3
) 305 ± 9 290 ± 6 220 ± 19*** 189 ± 4***§ 
Sa (cm
2
) 263 ± 18 252 ± 6 207 ± 34*** 160 ± 11*** 
Vva (cm
3
/cm
3
) 0.658 ± 0.009 0.664 ± 0.009 
0.739 ± 
0.019*** 
0.748 ± 
0.016*** 
Vvi (cm
3
/cm
3
) 0.247 ± 0.007 0.228 ± 0.007 
0.173 ± 
0.008*** 
0.163 ± 
0.009*** 
Vvv (cm
3
/cm
3
) 0.048 ± 0.005 0.055 ± 0.006 0.038 ± 0.014* 0.035 ± 0.005* 
VvA (cm
3
/cm
3
) 0.047 ± 0.004 0.054 ± 0.006 0.051 ± 0.009 0.054 ± 0.006 
 
Determinations were made in 10d-old pups; controls received the vehicle of KGF; n = 10 to 
18 for room air/control ; n = 10 to 19 individuals for room air/rhKGF. Sv(a,p), alveolar 
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surface density; Sa, total alveolar surface; Vva, alveolar airspace volume density; Vvi, 
interstitial volume density; Vvv, vascular volume density; VvA, airspace volume density of 
airways. Multiple comparisons by ANOVA and two-group comparisons by Fisher's post hoc 
test. Significant difference for: *p< 0.05 and ***p<0.001 as compared with room air-
controls ; § p< 0.05 as compared with hyperoxia-controls 
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Table 3. Determination of proportions of SP-B-positive and apoptotic (TUNEL positive) cells 
in the lungs of rat pups treated by rhKGF in room air or under hyperoxia 
 
 Room air  Hyperoxia  
 controls rhKGF controls rhKGF 
Total cell count / field 113 ± 7 125 ± 9 71 ± 4*** 62 ± 4*** 
SP-B
+
 cells / field 11.6 ± 1.2 15.3 ± 1.7* 11.5 ± 1.2 12.5 ± 0.8 
% SP-B
+
 cells 10.3 ± 0.8 12.0 ± 0.8 16.0 ± 0.9*** 20.0 ± 0.8***§ 
TUNEL
+
 cells / field 1.4 ± 0.3 1.5 ± 0.2 2.0 ± 0.2 1.3 ± 0.5 
% TUNEL
+
 cells 1.2 ± 0.2 1.2 ± 0.1 2.8 ± 0.3* 2.1 ± 0.8 
 
Determinations were made in 10d-old pups; controls received the vehicle of KGF; n = 3 per 
experimental group. Multiple comparisons by Kruskal Wallis test and two-group comparisons 
by Mann Whitney test. Significant difference for: *p<0.05 and ***p< 0.001 as compared with 
room air-controls ; § p< 0.001 as compared with hyperoxia-controls. 
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Table 4. Surfactant phospholipids in rat pups treated by rhKGF in room air or under 
hyperoxia 
 
 Room air  Hyperoxia  
 controls rhKGF controls rhKGF 
Lung-tissue phospholipids     
DSPC (nmol/mg prot.) 45.3 ± 2.0 40.7 ± 0.5
§
 53.3 ± 5.4 42.2 ± 3.6 
PG (nmol/mg prot.) 11.2 ± 0.7 9.9 ± 0.4 7.2 ± 0.8** 7.1 ± 0.3** 
Lung-lavage phospholipids     
TPL (nmol/ml) 31.3 ± 3.1 21.0 ± 1.4* 35.2 ± 0.1 31.1 ± 2.5 
DSPC (nmol/ml) 19.0 ±1.8 13.8 ± 0.8* 24.6 ± 1.2* 22.3 ± 1.1 
DSPC/TPL (%) 60.6 ± 1.0 65.6 ± 2.1 75.7 ± 3.6* 71.7 ± 3.1* 
 
Determinations were made in 5d-old pups for tissue phospholipids (n = 6 or 7) and in 7d-old 
pups for lung-lavage phospholipids (n = 4 or 5); controls received the vehicle of rhKGF. 
DSPC: disaturated phosphatidylcholine; PG: phosphatidylglycerol; TPL: total phospholipids. 
Multiple comparisons by ANOVA and two-group comparisons by Fisher's post hoc test. 
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Significant difference for: *p<0.05 and **p<0.01 as compared with room air-controls; 
§
p<0.05 as compared with hyperoxia-controls. In lung tissue, only PG was changed by 
hyperoxia, and this was unaffected by KGF. The proportion of DSPC (DSPC/TPL) in lung 
lavage fluid was increased by hyperoxia, but unchanged by KGF. 
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